Economy

Sucampo Pharmaceuticals, Inc. (SCMP)- Most Bizarre Stocks for the Day

Sucampo Pharmaceuticals, Inc. (SCMP)- Most Bizarre Stocks for the Day

Sucampo Pharmaceuticals, Inc.'s beta is 1.41 whilst the stock has an average true range (ATR) of 0.89.

A number of other research analysts have also issued reports on the stock.

SCMP's 10% Owner Kuno Sachiko Sell 1000000 shares of the company at a price of $12 on 2017-09-11. Furthermore on 8/21/17 Leerink Swann "Initiates Coverage On" the stock to Outperform at $15. Finally, UBS dropped their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, October 12th. Separately, 10% Owner Ueno Ryuji Sell 1000000 shares of the company at a price of $12 on 2017-09-11.

Investors who are keeping close eye on Sucampo Pharmaceuticals, Inc. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. (NASDAQ:SCMP) has "Buy" rating given on Tuesday, August 1 by Mizuho. (NASDAQ:SCMP). California State Teachers Retirement holds 42,818 shares or 0% of its portfolio. During the last month, the stock has changed 7.77% and performed 33.19% over the last 6 months. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $17.70.

The co's performance for 6 months was isolated positively of 53.69%, 1-year performance stands at 4.52% and year to date showing surged performance of 15.13%. The debt-to-equity ratio (D/E) was recorded at 4.48. Insider ownership decreased by a total of 2 million shares, which suggests that SCMP's key executives are feeling less optimistic about the outlook for the stock. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million for the quarter, compared to analysts' expectations of $58.05 million.

More news: Elon Musk Confirms Tesla is Working on Custom Hardware for Autopilot

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st.

Stock to Watch: Sucampo Pharmaceuticals, Inc. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Quantbot Tech Lp stated it has 0% in Sucampo Pharmaceuticals, Inc. However the six-month change in the insider ownership was recorded -97.83%, as well as three-month change in the institutional ownership was recorded 18.36%. They set a "buy" rating and a $14.00 target price on the stock.

Sucampo Pharmaceuticals, Inc stake is new for [reportingPerson]. Systematic Financial Management LP purchased a new position in shares of Sucampo Pharmaceuticals during the second quarter valued at approximately $1,648,000. "Ultimately, through all this investigation into the company's performance the analyst decides if their stock is a "buy", sell" or hold". Finally, Strs Ohio raised its holdings in shares of Sucampo Pharmaceuticals by 34.4% in the 2nd quarter. (NASDAQ:SCMP) have caught the attention of investors. However, the institutional investors are observed to own 67.00% of the total shares.

ILLEGAL ACTIVITY NOTICE: "Sucampo Pharmaceuticals (SCMP) Upgraded at BidaskClub" was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of United States and worldwide copyright and trademark laws. The original version of this report can be accessed at https://www.truebluetribune.com/2017/12/08/sucampo-pharmaceuticals-scmp-earns-daily-media-impact-rating-of-0-05.html. Louisiana State Employees Retirement System boosted its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.